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Abstract
Objective: To determine the cutoffs that optimized the agreement between
18F-Florbetapir positron emission tomography (PET) and Ab1-42, Ab1-40,
tTau, pTau and their ratios measured in cerebrospinal fluid (CSF) on the
LUMIPULSE G600II instrument, we quantified the levels of these four
biomarkers in 94 CSF samples from participants of the Sant Pau Initiative on
Neurodegeneration (SPIN cohort) using the Lumipulse G System with available
18F-Florbetapir imaging. Methods: Participants had mild cognitive impairment
(n = 35), AD dementia (n = 12), other dementias or neurodegenerative diseases
(n = 41), or were cognitively normal controls (n = 6). Levels of Ab1-42 were
standardized to certified reference material. Amyloid scans were assessed visually
and through automated quantification. We determined the cutoffs of CSF
biomarkers that optimized their agreement with 18F-Florbetapir PET and evalu-
ated concordance between markers of the amyloid category. Results: Ab1-42,
tTau and pTau (but not Ab1-40) and the ratios with Ab1-42 had good diagnos-
tic agreement with 18F-Florbetapir PET. As a marker of amyloid pathology, the
Ab1-42/Ab1-40 ratio had higher agreement and better correlation with amyloid
PET than Ab1-42 alone. Interpretation: CSF biomarkers measured with the
Lumipulse G System show good agreement with amyloid imaging in a clinical
setting with heterogeneous presentations of neurological disorders. Combination
of Ab1-42 with Ab1-40 increases the agreement between markers of amyloid
pathology.
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Introduction
Advances in the field of biomarkers have pushed forward
a redefinition of Alzheimer’s disease (AD) as a biological
construct.1 Under this definition, the ATN classification
system recognizes three general groups of biomarkers for
AD: biomarkers of b-amyloid plaques (A), biomarkers of
fibrillar tau (T) and biomarkers of neurodegeneration or
neuronal injury (N).1 These categories can be assessed by
using different modalities, but those that are more widely
implemented are cerebrospinal fluid (CSF) biomarkers
and imaging techniques. Amyloid positron emission
tomography (PET), CSF Ab1-42 and the ratio Ab1-42/
Ab1-40 correspond to the “A” category, Tau PET and CSF
pTau to the “T” category, whereas 18F-Fluorodeoxyglu-
cose-PET, anatomical MRI and tTau are considered mark-
ers of the “N” category.1 Within the “A” category, the
concordance between CSF Ab1-42 and amyloid PET imag-
ing is high, but not perfect.2–6 In fact, the Ab1-42/Ab1-40
ratio has shown to have better agreement with amyloid
PET imaging compared to levels of Ab1-42 alone.4,7–9
In recent years, fully automated platforms have been
developed for the analysis of CSF biomarkers. Recently,
four CSF analytes (Ab1-42, Ab1-40, tTau and pTau) have
been implemented on the fully automated Lumipulse G
System, but there are no validated cutoffs for these four
AD CSF biomarkers using this platform. Our aims were
to determine for the first time the cutoffs that optimized
the agreement between 18F-Florbetapir PET and Ab1-42,
Ab1-40, tTau, pTau and their ratios measured in CSF on
the LUMIPULSE G600II instrument, and to evaluate the
concordance between markers of the amyloid category.
Methods
Study participants
We included 94 participants from the Sant Pau Initiative
on Neurodegeneration (SPIN cohort) recruited between
November 2013 and September 2017 who had available
CSF samples and 18F-Florbetapir PET imaging (Table 1).
The SPIN cohort is a multimodal research cohort for bio-
marker discovery and validation that includes participants
with different neurodegenerative dementias, mild cogni-
tive impairment and cognitively normal controls. All par-
ticipants receive an extensive neurological and
neuropsychological evaluation and undergo structural 3T
brain MRI, blood extraction, and lumbar puncture for
CSF biomarkers. A subset of participants also receives
molecular imaging such as 18F-Fluorodeoxyglucose-PET,
amyloid and/or Tau PET. More information on the SPIN
cohort can be found at https://santpaumemoryunit.com/
Table 1. Clinical and demographic characteristics of all participants and based on visual amyloid PET status.
All participants Amyloid positive Amyloid negative P value
n (%) 94 (100%) 59 (63%) 35 (37%) –
Age, years 73.0 (7.6) 73.5 (7) 72.1 (8.5) 0.405*
Sex, female/male (% female) 50/44 (53%) 32/27 (54%) 18/17 (51%) 0.960†
APOEe4 +/ (% +) 56/37 (60%) 30/28 (52%) 7/28 (20%) 0.004†
MMSE score 24.7 (4.1) 24.1 (4.3) 25.7 (3.6) 0.052*
Time difference between amyloid PET and lumbar puncture, days 152 (86) 151 (78) 156 (100) 0.792*
Clinical diagnosis, n (%) 0.067†
Cognitively normal 6 (100%) 3 (50%) 3 (50%) –
Mild cognitive impairment 35 (100%) 23 (66%) 12 (34%) –
AD dementia 12 (100%) 11 (92%) 1 (8%) –
Dementia with Lewy bodies 30 (100%) 18 (60%) 12 (40%) –
Frontotemporal dementia 9 (100%) 3 (33%) 6 (67%) –
Other diagnoses 2 (100%) 1 (50%) 1 (50%) –
CSF biomarkers
Ab1-42, pg/mL 745 (379) 608 (213) 985 (474) <0.001*
Ab1-40, pg/mL 12252 (3944) 12782 (3954) 11360 (3816) 0.089*
tTau, pg/mL 566 (363) 667 (375) 397 (273) <0.001*
pTau, pg/mL 93 (71) 114 (71) 58 (58) 0.001*
Ab1-42/Ab1-40 0.064 (0.028) 0.049 (0.015) 0.088 (0.027) <0.001*
tTau/Ab1-42 0.95 (0.76) 1.17 (0.63) 0.57 (0.81) <0.001*
pTau/Ab1-42 0.16 (0.15) 0.20 (0.12) 0.09 (0.16) <0.001*
Unless otherwise specified, results are presented as mean (standard deviation).
MMSE, Mini-mental state examination; AD, Alzheimer’s disease; CSF, cerebrospinal fluid; PET, positron emission tomography.
P-values were calculated by comparing amyloid–positive and amyloid–negative participants using Welch two-sample t-test (*) or Fisher’s exact test (†).
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our-research/spin-cohort (Alcolea et al., submitted). All
participants gave written consent, and the ethics commit-
tee of Hospital Sant Pau approved all procedures included
in this study.
CSF samples acquisition and analysis
CSF samples were collected in 10 mL polypropylene tubes
(Sarstedt, Ref#62.610.018) and transferred to the Sant Pau
Memory Unit’s laboratory where they were processed
within the first 2 h after acquisition. After centrifugation
(2000g 9 10 min, 4°C), volumes of 0.5 mL of CSF were
aliquoted into polypropylene tubes (Sarstedt,
Ref#72.694.007) and stored at 80°C until analysis.
On the day of the analysis, samples were thawed at
room temperature and the tubes were vortexed for 5–
10 sec. To avoid the effect of multiple freeze-thaw cycles,
aliquots used in this study had not been thawed before.
Ab1-42, Ab1-40, tTau and pTau were quantified directly
from the storage tubes containing 0.5 mL of CSF using
the Lumipulse G b-Amyloid 1-42, b-Amyloid 1-40, Total
Tau and pTau 181 assays on LUMIPULSE G600II auto-
mated platform (Fujirebio) and following the manufac-
turer’s instructions. We used an adapter to fit the tubes
in the equipment. We used the same batch of reagents for
each biomarker throughout the study, and for each sam-
ple, we measured all four analytes from the same aliquot
and in the same run. The platform was configured to
start the analysis with Ab1-42, followed by Ab1-40, tTau
and pTau. Buffer-based quality control testing was per-
formed at the beginning of each test day to ensure that
all measured values of each control level (low, medium
and high) were within the target ranges.
The results of the Lumipulse G b-Amyloid 1-42 pre-
sented in this study have been standardized according to
certified reference material developed by the International
Federation of Clinical Chemistry and Laboratory Medi-
cine as recommended by their working group for CSF
proteins.10 Briefly, values of the calibration standards of
the LUMIPULSE G600II were adapted to the certified ref-
erence material resulting in an adjustment of concentra-
tions that was linearly proportional throughout the range.
The aim of standardization to certified reference material
is to harmonize immunoassays of Ab1-42 to make results
comparable across different platforms.
Ab1-42, Ab1-40, tTau and pTau levels in CSF from
participants of this study had been measured previously
using other immunoassays (INNOTEST b-AMYLOID(1-
42), INNOTEST hTAU Ag, and INNOTEST PHOSPHO-
TAU(181P), Fujirebio Europe; and High Sensitivity Human
Amyloid b40, Merck-Millipore), and these results were
available in our database for their comparison with the
LUMIPULSE analyses.11–15
The personnel involved in the CSF analyses for this
study were blinded to the clinical diagnosis and to previ-
ous biomarker determinations.
Amyloid-PET imaging acquisition, visual
assessment and quantitative analysis
All participants underwent amyloid PET imaging with
18F-Florbetapir as described elsewhere.13 PET data were
acquired using a Philips Gemini TF scan 50 min after
injection of 370mBq of 18F-Florbetapir. After obtaining
the transmission data, brain PET dynamic acquisition was
performed (2 9 5 min frames). The reconstruction
method was iterative (LOR RAMBLA, three iterations and
33 subsets) with a 128 9 128 image size, 2 mm pixel size
and slice thickness.
Three expert readers (V.C., D.L-M. and A.F-L.) blind to
clinical diagnosis and to CSF biomarkers visually rated all
PET scans. Following manufacturer’s protocol, scans were
classified as “positive” when one or more areas showed
increased cortical gray matter signal resulting in reduced or
absent contrast between gray matter and white matter. Scans
were classified as “negative” when the contrast between gray
matter and white matter was clear. Final classification as
“positive” or “negative” was decided upon agreement of at
least two of three readers. Mean inter-reader overall agree-
ment was 88.4% (Min = 87.0%, Max = 90.2%).
We also quantified amyloid deposition. Each partici-
pant’s PET scan was spatially normalized to a MNI152 18F-
Florbetapir template using a linear and nonlinear transfor-
mation.16 Mean 18F-Florbetapir uptake was measured
across frontal, lateral parietal, lateral temporal and ante-
rior/posterior cingulate. Then, the 18F-Florbetapir stan-
dardized uptake value ratio (SUVR) map was extracted
using the whole cerebellum as reference.17 The PET scans
of five participants were not suitable for 18F-Florbetapir
quantification and excluded of quantitative analyses.
Statistical analysis
We performed receiver operating characteristic (ROC)
analysis for Ab1-42, Ab1-40, tTau, pTau and the ratios
Ab1-42/Ab1-40, tTau/Ab1-42 and pTau/Ab1-42 to calcu-
late areas under the curve (AUC) with 95% confidence
intervals (DeLong). We compared ROC curves by two-
sided bootstrapping with 2000 replications. For biomark-
ers and ratios that showed AUC higher than 0.70, we
determined positive percent agreement (PPA or sensitiv-
ity) and negative percent agreement (NPA or specificity)
and calculated optimal cutoffs maximizing their Youden J
index (PPA + NPA  1). We calculated overall percent
agreement (OPA) between CSF biomarker cutoffs and
amyloid PET visual interpretation as the sum of
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participants classified as “positive” or as “negative” by
both modalities over the total number of participants. We
also analyzed the correlation of CSF biomarkers with glo-
bal amyloid accumulation by fitting quadratic models and
calculated the agreement of CSF biomarkers cutoffs with
the PET scans quantification status applying a previously
described SUVR cutoff of 1.11.17 Level of significance was
set at a = 0.05. We used Analyse-it statistical software
for the selection of optimal cutoffs and packages “car”
(v.3.0-3, Fox&Weisberg 2019), “pROC” (v.1.15.0, Robin
et al 2011), “grid” (R core team 2019) and “ggplot2”
(v.3.1.1, Wickham 2016) as implemented in R statistical
software (v 3.6.0) for plots and statistical analyses.
Results
Study participants
We included 94 participants in the study. Table 1 sum-
marizes demographic characteristics and biomarker
results. There were no differences in age or sex between
both groups. As expected, the amyloid–positive group
had a higher proportion of APOEe4 carriers compared to
the amyloid–negative group (52% and 20%, respectively;
P = 0.004).
Quantification of Ab1-42, Ab1-40, tTau and
pTau concentrations on the LUMIPULSE
G600II
We measured Ab1-42, Ab1-40, tTau and pTau levels
simultaneously on the Lumipulse G System. Their levels in
the overall study population ranged from 315 to 2280 pg/
mL for Ab1-42, 4585 to 25925 pg/mL for Ab1-40, 141 to
1902 pg/mL for tTau, and 18 to 340 pg/mL for pTau.
The analyses were divided over three calibration runs
on the LUMIPULSE G600II, and the calibration status
was valid for all samples. Mean interassay coefficients of
variation are displayed in Figure S1.
Most CSF samples included in this study had previ-
ously been analyzed using other immunoassays, and their
results were available in our database. Although these his-
toric results were obtained in the context of routine clini-
cal assessment by using different batches, and therefore a
side-to-side precision analysis could not be performed, we
explored their correlation with the Lumipulse G quantifi-
cations. The Lumipulse G assays for Ab1-42, tTau and
pTau showed very high correlation with values previously
measured with Fujirebio’s INNOTEST ELISA (Pearson’s r
of 0.94, 0.95 and 0.95, respectively, all P < 0.001). The
Lumipulse G assay for Ab1-40 showed moderate correla-
tion with values measured with Merck-Millipore’s ELISA
(Pearson’s r of 0.76, P < 0.001). On the Lumipulse G
system, tTau and pTau were highly correlated (Pearson’s
r of 0.98, P < 0.001).
Agreement between 18F-Florbetapir visual
status and CSF biomarkers
As displayed in Figure 1A, of individual biomarkers, tTau
and pTau had the highest accuracy and showed AUC of 0.80
(95%CI 0.70–0.89, P < 0.001) and 0.84 (95%CI 0.75–0.93,
P < 0.001), respectively. Ab1-42 had fair accuracy with an
AUC of 0.76 (95%CI 0.65–0.86, P < 0.001) and Ab1-40
alone was not useful for the detection of the visual status of
amyloid scans (AUC 0.59; 95%CI 0.47–0.71, P = 0.134).
Figure 1B shows that the combination of Ab1-42 with
a second analyte resulted in significant increases of accu-
racy. The AUC of Ab1-42/Ab1-40 was 0.86 (95%CI 0.77–
0.96, P < 0.001), higher than that of Ab1-42 alone
(D = 2.5; P = 0.01) or Ab1-40 alone (D = 4.0;
P < 0.001). tTau/Ab1-42 had an AUC of 0.87 (95%CI
0.78–0.95, P < 0.001), higher than that of tTau
(D = 2.2; P = 0.03), and pTau/Ab1-42 had an AUC of
0.88 (95%CI 0.79–0.97, P < 0.001), higher than that of
pTau alone (D = 1.9; P = 0.05). There were no signifi-
cant differences in the AUC of the three ratios, and com-
bining a third biomarker in the ratios did not improve
their accuracy (data not shown).
CSF biomarker cutoffs based on visual
interpretation of amyloid status
For those biomarkers and ratios that showed AUC higher
than 0.70, we used ROC analysis to obtain PPA, NPA and
OPA for all possible cutoffs. As displayed in Figure 2, in the
case of single biomarkers, Ab1-42, tTau and pTau, the selec-
tion was based on clear Youden peaks at 916, 456 and
63 pg/mL, respectively. For the ratios Ab1-42/Ab1-40,
tTau/Ab1-42 and pTau/Ab1-42, plots showed plateau stages
indicating that a wide range of cutoffs yielded similar You-
den indices. Best cutoffs for ratios were 0.062 for Ab1-42/
Ab1-40, 0.62 for tTau/Ab1-42, and 0.068 for pTau/Ab1-42.
Figure 3 displays the agreement between visual status of
18F-Florbetapir and CSF biomarker cutoffs. For Ab1-42,
tTau and pTau, the OPA values between visual status and
CSF biomarkers status were 79%, 78% and 81%, respec-
tively. The ratio of Ab1-42 with Ab1-40, tTau and pTau
increased the OPA to 84%, 82% and 88%, respectively.
Markers of amyloid and importance of
assessing a second biomarker
Within each CSF biomarker status, the proportion of pos-
itive amyloid scans varied when a second biomarker or
ratio was taken into account. Figure S2 shows the
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proportion of positive amyloid scans within each combi-
nation of two CSF biomarkers or ratios, and illustrates
the importance of considering a second biomarker. Of all
participants with low CSF levels of Ab1-42, regardless of
the Ab1-42/Ab1-40 ratio status, 77% (56 out of 73) had a
positive amyloid scan. This proportion increased to 87%
(52 out of 60) within this group when the Ab1-42/Ab1-
40 ratio was also low but decreased to 31% (four out of
13) when the Ab1-42/Ab1-40 ratio was high. In the group
of participants with high CSF levels of Ab1-42, the impact
of considering the Ab1-42/Ab1-40 status had no effect, as
in all participants within this group the Ab1-42/Ab1-40
ratio was also high. These results highlight the importance
of using the Ab1-42/Ab1-40 ratio over Ab1-42 alone in
the assessment of brain amyloidosis, especially in patients
with low CSF levels of Ab1-42.
Agreement of CSF cutoffs with amyloid
quantification
We next processed amyloid PET scans to obtain quantifi-
cation values of amyloid deposition. In our study, the
previously validated SUVR value of 1.11,17 showed 83%
PPA, 76% NPA, and 81% OPA with visual classification.
As displayed in Figure 4, scans that were divergently clas-
sified as “negative” or “positive” by one of the three
raters showed intermediate SUVR values compared to
scans that were unanimously classified.
As seen in Figure 5, the agreement of CSF cutoffs with
amyloid PET quantification was similar to that with
visual classification for all biomarkers. We studied the
correlation between each CSF biomarker and global amy-
loid accumulation by fitting quadratic models. In these
models, the adjusted coefficients of determination (R2)
were higher for all ratios compared to individual
biomarkers. The combination of Ab1-42 with Ab1-40
increased the R2 value to 0.44 (P < 0.001), indicating that
this ratio reflects the amyloid deposition better than Ab1-
42 alone. Stratified analysis by 18F-Florbetapir visual sta-
tus showed lower R2 values for all biomarkers, which sug-
gests that the correlation observed between CSF
biomarkers and amyloid PET quantification is partially
mediated by an amyloid-status effect. In this stratified
analysis, the highest correlation of SUVR values was
found with the Ab1-42/Ab1-40 ratio in the amyloid–neg-
ative group (R2 = 0.42; P < 0.001).
Discussion
In our study, we determined cutoffs for four CSF
biomarkers for AD (Ab1-42, Ab1-40, tTau and pTau)
and their ratios measured on the fully automated LUMI-
PULSE G600II platform to optimize their concordance
with 18F-Florbetapir PET. We calibrated Ab1-42 levels to
certified reference material, recently developed to harmo-
nize immunoassays across different platforms, and found
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that the ratios Ab1-42/Ab1-40, tTau/Ab1-42 and pTau/
Ab1-42 had better diagnostic agreement with visual
assessment of amyloid scans than single biomarkers. As a
marker of amyloid pathology, the Ab1-42/Ab1-40 ratio
had higher agreement with amyloid PET visual status and
showed better correlation with amyloid load quantifica-
tion compared to Ab1-42 alone.
The agreement between amyloid imaging and AD
CSF biomarkers has previously been studied by using
other automated immunoassays.3,4,8 Our results are in
line with previous studies showing a good overall agree-
ment between amyloid imaging and AD CSF biomark-
ers, higher for ratios than for single analytes.3,4
However, specific cutoff points for CSF biomarkers
differ between these studies, and several methodological
differences can explain these discrepancies. First, preana-
lytical conditions, such as the type of collection and
storage tubes, are different between studies, and these
factors are known to have a great impact on the abso-
lute values of CSF biomarkers, especially for Ab1-
42.18,19 Second, some analytical particularities for each
immunoassay and platform used in these studies (speci-
ficity of the antibodies, time of incubation) result in
diverse CSF biomarker measures. Calibration of all
automated platforms to certified reference material, cur-
rently underway, will minimize this issue in the future.
Likewise, differences in the affinity of PET radiotracers
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18F-Florbetapir) can lead to disparities in the selection
of cutoffs. Third, the composition of the populations
was not the same across studies. Schindler et al. ana-
lyzed data from community–dwelling volunteers,4
whereas Janelidze et al. obtained their results from
patients with mild cognitive impairment and subjective
cognitive decline from the BioFINDER cohort.8 Hansson
et al. studied CSF of participants from ADNI and Bio-
FINDER cohorts, that included cognitively normal vol-
unteers, patients with mild cognitive impairment and
patients with AD dementia.3 In our study, we addition-
ally included patients with other dementias or neurode-
generative diseases, which might reflect more realistically
the application of biomarkers in daily clinical practice.
As in a number of other studies, the cutoffs in our
study were selected by maximization of Youden J index.
This approach balances sensitivity and specificity and is
equivalent to maximize accuracy for a pre-test disease
prevalence of 50%.20 However, other strategies might be
useful in certain clinical scenarios.21 For instance, for
screening purposes, it might be helpful to apply cutoffs
with high sensitivity, even when their specificity is
lower. For patients with clinically challenging diagnoses
or in clinical trials, however, high specificity might be
preferable. Other possible approaches include the
sequential application of biomarker cutoffs.
The LUMIPULSE G600II has incorporated the possibil-
ity of measuring CSF levels of Ab1-40. In previous stud-
ies, and ours, this biomarker alone was not useful for the
detection of brain amyloid.4,7,9 Both Ab1-42 and the
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Figure 3. Agreement of visual amyloid status with single and combined CSF biomarkers. Panels A, B and C display scatterplots of CSF biomarker
levels. Dashed lines indicate cutoffs that yielded maximum Youden J Index in the receiver operating characteristic analysis for each biomarker or
ratio. PPA, Positive Percent Agreement; NPA, Negative Percent Agreement; OPA, Overall Percent Agreement.
A
Rater 1
OPA=77%
Rater 2
OPA=78%
Rater 3
OPA=82%
Global
OPA=81%
Negative Positive Negative Positive Negative Positive Negative Positive
0.75
1.00
1.25
1.50
1.75
SU
VR
18F−Florbetapir
Visual Status
Positive
Negative
B
OPA = 81% OPA = 45% OPA = 100% OPA = 86%
0.75
1.00
1.25
1.50
1.75
0/3 1/3 2/3 3/3
Number of raters that classified as 'Positive'
SU
VR
18F−Florbetapir
Visual Status
Positive
Negative
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Ab1-42/Ab1-40 ratio are included in the “A” category of
the ATN classification system together with amyloid PET,
but in line with other studies,7,9,22,23 we found that the
Ab1-42/Ab1-40 ratio had better agreement with visual
amyloid status and higher correlation with brain amyloid
quantification. Our results are in line with previous litera-
ture that suggests that the use of the Ab1-42/Ab1-40 ratio
could compensate individual differences in amyloid pre-
cursor protein processing that otherwise might lead to
false positive or false negative Ab1-42 CSF levels.24,25 This
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Figure 5. Scatterplots and correlations of amyloid quantification values with individual biomarkers (A, C, E) and ratios (B, D, F). Correlation
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information adds to the fact that using the Ab1-42/Ab1-
40 ratio has proven to partially mitigate the effect of
some preanalytical confounders that have been described
to alter the results of amyloid levels.26–28 Altogether, our
data suggest that the use of the Ab1-42/Ab1-40 ratio
would be more reliable in clinical practice than Ab1-42
alone as a marker of amyloidosis and that this combina-
tion should be used in routine.
The main strength of our study is that four AD CSF
biomarkers (Ab1-42, Ab1-40, tTau and pTau) measured
simultaneously with the automated Lumipulse G System
were compared for the first time to 18F-Florbetapir PET
to calculate amyloid–based cutoffs. In addition, this is, to
our knowledge, the first study to present Ab1-42 levels
that have been standardized to certified reference mate-
rial, recently developed to harmonize immunoassays
across different platforms. Standardized values will make
our study more easily comparable to future studies.
Moreover, to avoid possible sources of variability, we fol-
lowed homogeneous CSF preanalytical and analytical pro-
cedures and used the same batch of reagents for all
measurements. Also, the inclusion of participants with
neurodegenerative diseases outside the AD spectrum pro-
vides a more realistic application of biomarkers in daily
clinical practice.
However, we are aware of some limitations. We did not
test the effect that deviations from our preanalytical proto-
col would have on the final cutoffs, and therefore, the cut-
offs that we report should be taken cautiously under other
operating procedures. Some of the clinical categories in
our study included a small number of participants.
Although we used amyloid positivity/negativity as the gold
standard in our study, the composition of the sample in
terms of clinical diagnosis might be relevant for the inter-
pretation and applicability of our results. Additionally,
only very few participants had additional Tau imaging
and/or 18F-Fluorodeoxyglucose-PET, and we could not
compare the agreement of CSF pTau and tTau with
molecular imaging markers of the “T” and the “N” cate-
gories of the ATN classification. Likewise, as participants
in this study are part of a living cohort, neuropathological
confirmation is not available at this moment.
In this study, we found that the Ab1-42 ratios to Ab1-
40, tTau and pTau in CSF show a good agreement with
amyloid visual status and that the Ab1-42/Ab1-40 ratio
had better correlation with the amount of amyloid bur-
den compared to Ab1-42 alone. The understanding of the
agreement between CSF biomarkers and amyloid imaging
is crucial to identify situations in which these two modal-
ities might not be interchangeable. This information has
to be taken into consideration both in the diagnostic
assessment in clinical practice and in the selection of par-
ticipants in clinical trials.
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